Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
1999-11-23
pubmed:abstractText
We examined some immunological parameters, particularly cytokines and soluble factors in collagen diseases complicated with essential hypertension. We also investigated the effects of Nilvadipine on immunological parameters after treatment with this drug for six months. The frequency of helper/inducer T cells (CD4+ CD8- cells, CD4+ CD45RA- cells) decreased in the peripheral blood on a 6 month treatment with nilvadipine. There was a significant decrease of suppressor/inducer T cells (CD4+ 45RA+ cells), and an insignificant decrease of activated T cells (CD3+ HLA-DR+ cells) and memory T cells (CD45RA- CD45RO+ cells) after treatment. Before treatment with Nilvadipine, interleukin-1beta, tumor necrosis factor-a, and interleukin-6 levels increased higher in the patients than in healthy volunteers. However, interleukin-1beta and interleukin-6 concentrations tended to decrease after treatment with Nilvadipine. Besides, tumor necrosis factor-alpha decreased significantly after treatment. The soluble interleukin-2 receptor concentrations also showed a decreased tendency after treatment, although high concentrations were found in the patients before treatment. In contrast, soluble human leukocyte antigen-1 and soluble thrombomodulin levels showed no significant change after treatment. These results suggest that Nilvadipine inhibits the generation of cytokines derived from activated T lymphocytes. Nilvadipine, calcium antagonist, may be useful for inhibition of vascular complication in collagen diseases.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1064-1963
pubmed:author
pubmed:issnType
Print
pubmed:volume
21
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1177-88
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:10513835-Adult, pubmed-meshheading:10513835-Aged, pubmed-meshheading:10513835-Antigens, CD45, pubmed-meshheading:10513835-Blood Pressure, pubmed-meshheading:10513835-CD4-CD8 Ratio, pubmed-meshheading:10513835-Calcium Channel Blockers, pubmed-meshheading:10513835-Collagen Diseases, pubmed-meshheading:10513835-Cytokines, pubmed-meshheading:10513835-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:10513835-Female, pubmed-meshheading:10513835-Flow Cytometry, pubmed-meshheading:10513835-HLA-DR1 Antigen, pubmed-meshheading:10513835-Humans, pubmed-meshheading:10513835-Hypertension, pubmed-meshheading:10513835-Interleukin-1, pubmed-meshheading:10513835-Interleukin-6, pubmed-meshheading:10513835-Lymphocyte Activation, pubmed-meshheading:10513835-Male, pubmed-meshheading:10513835-Middle Aged, pubmed-meshheading:10513835-Nifedipine, pubmed-meshheading:10513835-Receptors, Interleukin-2, pubmed-meshheading:10513835-Retrospective Studies, pubmed-meshheading:10513835-T-Lymphocyte Subsets, pubmed-meshheading:10513835-T-Lymphocytes, Helper-Inducer, pubmed-meshheading:10513835-Treatment Outcome, pubmed-meshheading:10513835-Tumor Necrosis Factor-alpha
pubmed:year
1999
pubmed:articleTitle
Effects of nilvadipine on cytokine-levels and soluble factors in collagen disease complicated with essential hypertension.
pubmed:affiliation
The First Department of Internal Medicine, Kansai Medical University, Moriguchi, Osaka, Japan.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't